INTRODUCTION
Patients with malignancy are at increased risk for vascular thromboembolism; thromboembolic events are a significant cause of morbidity and mortality (1) . In patients undergoing chemotherapy, the risk for thromboembolism is approximately six times higher than that in the non-cancer population (1) , and most of these thrombotic events occur in the venous system. Although the incidence of arterial thromboembolism is lower, it has, nevertheless, been reported to be 3.8% among cancer patients (2) .
Capecitabine is an oral prodrug of 5-fluorouracil (5-FU), which is commonly used to treat gastric, colon, and breast cancers. The most common complications associated with capecitabine administration are hand-foot syndrome, neutropenia, fatigue and gastrointestinal symptoms, such as, diarrhea, vomiting, nausea, and abdominal pain (3). Cardiovascular complications are uncommon; however, cardiac toxicities, such as arrhythmias, cardiomyopathy, angina, and myocardial infarction, have been reported (4) . However, acute aortic thrombus is an extremely rare toxicity that requires early diagnosis and prompt treatment because it can be a potential source of cerebral, visceral, or lower extremity emboli. We report a case of acute aortic thrombosis in a patient who underwent capecitabine treatment for colon cancer.
Case RepORT
A 63-year-old man was diagnosed with adenocarcinoma in the ascending colon and associated bowel obstruction. Right The elevated risk for thromboembolic events in cancer patients has been well documented. Chemotherapy is considered to be one of the most important risk factors for cardiovascular complications such as arrhythmias, cardiomyopathy, angina, and myocardial infarction. However, acute aortic thrombosis is an extremely rare complication in patients receiving chemotherapy. The authors report a case of acute aortic thrombosis after adjuvant capecitabine chemotherapy for colon cancer. (Fig. 1C) , with acute thrombosis evident in the SMA (Fig. 1D ). There was no CT scan revealed diffuse small bowel wall necrosis with pneumatosis intestinalis (Fig. 1E, F) . At emergency exploratory laparotomy, the entire small bowel was necrotic and nonviable;
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consequently, an open-and-close operation was performed. The patient was then treated conservatively but died four days later.
DIsCUssION
We report a case of long segmental, acute aortic thrombus that developed in a patient with colon cancer after a second cycle of capecitabine chemotherapy. Arterial thrombosis is rare, and is usually associated with underlying atherosclerosis and/or aneurysmal change (5) . At the time of colon cancer diagnosis, baseline CT revealed atherosclerotic changes in the aorta and SMA, presumably related to older age, hypertension, and tobacco smoking. Mesenteric artery stenosis is usually due to atherosclerosis, and results in insufficient blood flow to the small intestine, causing chronic intestinal ischemia (5).
Chemotherapy is a well-known risk factor for thromboembolism in cancer patients; however, in most cases, it involves the venous system (1). In situ arterial thrombosis is rarely associated with cytotoxic chemotherapy, and is regarded to be a potential side effect of anti-angiogenic therapies. The risk for arterial thrombosis in patients undergoing vascular endothelial growth factor (VEGF) receptor-targeted therapy has been reported to be approximately twice that of control patients (6, 7). Bevaci- In conclusion, capecitabine-induced aortic thrombosis is a rare but important complication. Physicians who treat patients with capecitabine need to be mindful of the possibility of arterial thrombosis, especially in patients with underlying atherosclerosis.
